JP2016535030A5 - - Google Patents

Download PDF

Info

Publication number
JP2016535030A5
JP2016535030A5 JP2016526336A JP2016526336A JP2016535030A5 JP 2016535030 A5 JP2016535030 A5 JP 2016535030A5 JP 2016526336 A JP2016526336 A JP 2016526336A JP 2016526336 A JP2016526336 A JP 2016526336A JP 2016535030 A5 JP2016535030 A5 JP 2016535030A5
Authority
JP
Japan
Prior art keywords
polymeric material
inner layer
soluble
drug
separation layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016526336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535030A (ja
JP6273356B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/072648 external-priority patent/WO2015062640A1/en
Publication of JP2016535030A publication Critical patent/JP2016535030A/ja
Publication of JP2016535030A5 publication Critical patent/JP2016535030A5/ja
Application granted granted Critical
Publication of JP6273356B2 publication Critical patent/JP6273356B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016526336A 2013-10-29 2013-10-29 遅延放出性薬物製剤 Active JP6273356B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/072648 WO2015062640A1 (en) 2013-10-29 2013-10-29 A delayed release drug formulation

Publications (3)

Publication Number Publication Date
JP2016535030A JP2016535030A (ja) 2016-11-10
JP2016535030A5 true JP2016535030A5 (enExample) 2016-12-22
JP6273356B2 JP6273356B2 (ja) 2018-01-31

Family

ID=49515360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526336A Active JP6273356B2 (ja) 2013-10-29 2013-10-29 遅延放出性薬物製剤

Country Status (25)

Country Link
US (1) US10799515B2 (enExample)
EP (2) EP3542791A1 (enExample)
JP (1) JP6273356B2 (enExample)
KR (2) KR102237356B1 (enExample)
CN (2) CN105555260B (enExample)
AU (2) AU2013404367B2 (enExample)
BR (2) BR122020013726B1 (enExample)
CA (1) CA2923063C (enExample)
CR (1) CR20160192A (enExample)
CU (1) CU20160055A7 (enExample)
EA (1) EA032504B1 (enExample)
HK (1) HK1222547A1 (enExample)
IL (2) IL244260B (enExample)
MA (1) MA38847B2 (enExample)
MX (2) MX388063B (enExample)
MY (1) MY189394A (enExample)
NZ (2) NZ747731A (enExample)
PH (2) PH12020551522A1 (enExample)
SA (2) SA116370660B1 (enExample)
SG (1) SG11201600501UA (enExample)
TN (1) TN2016000119A1 (enExample)
TW (3) TWI680774B (enExample)
UA (1) UA117260C2 (enExample)
WO (1) WO2015062640A1 (enExample)
ZA (1) ZA201600630B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2659881T1 (en) 2012-04-30 2018-03-30 Tillotts Pharma Ag Formulation of the delayed release medicinal product
CN108283000B (zh) 2015-09-23 2021-04-13 凯瑞康宁生物工程(武汉)有限公司 γ-羟基丁酸的前药及其组合物和用途
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
WO2019126200A1 (en) * 2017-12-21 2019-06-27 Pepsico, Inc. Multi-ingredient ephemeral beverage pod for making a beverage
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
EP3662902B1 (en) * 2018-12-07 2024-07-31 Tillotts Pharma AG Colonic drug delivery formulation
ES3002632T3 (en) 2018-12-07 2025-03-07 Tillotts Pharma Ag Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
CN114828833A (zh) 2019-12-11 2022-07-29 赢创运营有限公司 包含碱剂和肠溶包衣层的剂型
ES2975442T3 (es) 2019-12-11 2024-07-05 Evonik Operations Gmbh Forma farmacéutica para su uso en el tratamiento o la prevención de una enfermedad

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) * 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CA2236605A1 (en) 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
ES2198872T3 (es) 1999-12-16 2004-02-01 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Preparaciones farmaceuticas multiunitarias gastrorresistentes que contienen piroxicam.
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780L (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
CN1293867C (zh) * 2001-05-25 2007-01-10 爱诗爱诗制药株式会社 药物复合制剂
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
EP1560597A4 (en) 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED CANCER GENES, POLYPEPTIDES CODED THEREIN, AND METHOD OF USE THEREOF
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2004058228A1 (en) 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1904039A2 (en) 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Controlled release dosage formulation of duloxetine
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) * 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
WO2008117814A1 (ja) 2007-03-26 2008-10-02 Teikoku Seiyaku Co., Ltd. 大腸送達用経口製剤
PL2152250T3 (pl) 2007-05-07 2020-06-15 Evonik Röhm Gmbh Stałe postaci dawkowania zawierające otoczkę dojelitową o przyspieszonym uwalnianiu leku
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
EP2486918A4 (en) 2009-10-09 2014-02-26 Yungjin Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION WITH BOTH IMMEDIATE AND DELAYED RELEASE
EP2384746A3 (en) * 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
WO2012075015A2 (en) 2010-11-29 2012-06-07 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
US10799460B2 (en) 2011-09-07 2020-10-13 Roland SAUR-BROSCH Formulation for the controlled release of one or several substances in the digestive tract of a mammal
CN102319218B (zh) 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
SI2659881T1 (en) 2012-04-30 2018-03-30 Tillotts Pharma Ag Formulation of the delayed release medicinal product
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool

Similar Documents

Publication Publication Date Title
HRP20180965T1 (hr) Formulacija lijeka s produženim otpuštanjem
RU2015110825A (ru) Устойчивая к действию желудочного сока фармацевтическая или нутрицевтическая композиция со стойкостью к влиянию этанола
RU2015110824A (ru) Фармацевтическая или нутрицевтическая композиция с замедленным высвобождением и стойкостью к воздействию этанола
UA117260C2 (uk) Лікарський препарат з відстроченим вивільненням
AR103981A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención
RU2013141534A (ru) Составы l-ментола, состоящие из множества частиц, и связанные с ними способы
JP2014520871A5 (enExample)
CN106456554A (zh) 修饰释放的包衣胶囊
HRP20190727T1 (hr) Formulacija odgođenog otpuštanja lijeka
RU2015140119A (ru) Таблетка, покрытая кишечнорастворимым покрытием
JP2009200496A5 (enExample)
WO2011045775A4 (en) A delayed release pharmaceutical composition of mesalamine
HRP20200891T1 (hr) Laktoferin za liječenje upalnih bolesti crijeva (ibd) povezanih s bakterijskim napadom
CN103989661A (zh) 西地那非口腔速溶膜剂及其制备方法
ZA202103678B (en) Colonic drug delivery formulation
CN102579388A (zh) 美沙拉秦结肠定位给药缓释片的制备
JP2014015438A5 (enExample)